Lipid profile changes associated with antiretroviral therapies in a real-world cohort

CONCLUSIONS: The lipid profile among elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate group worsened throughout the follow-up, both in naïve and experienced patients, not so remarkable in the dolutegravir/abacavir/lamivudine group. Both regimens were well tolerated, with similar rates of cardiovascular events.PMID:37673703 | DOI:10.1016/j.farma.2023.07.005

Source: Farmacia Hospitalaria - September 6, 2023 Category: Drugs & Pharmacology Authors: Sandra Rotea-Salvo V íctor Giménez-Arufe Alejandro Mart ínez-Pradeda Carla Fern ández-Oliveira Álvaro Mena-de-Cea Luis Margusino-Frami ñán Isabel Mart ín-Herranz Purificaci ón Cid-Silva Source Type: research